TRIB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	13 876.00
Średni wolumen	18 094.00
Kapitalizacja rynkowa	13.81M
EPS	$0 ( 2024-03-28 )
Następna data zysków	( $-0.600 ) 2024-07-04
Last Dividend	$0.220 ( 2015-06-05 )
Next Dividend	$0 ( N/A )
P/E	-0.0900
ATR14	$0.0300 (1.66%)

Insider Trading

Date	Person	Action	Amount	type
2004-02-13	Robert R Mccormick Tribune Foundation	Sell	65 200	Common Stock
2004-02-17	Robert R Mccormick Tribune Foundation	Sell	92 000	Common Stock
2004-02-18	Robert R Mccormick Tribune Foundation	Sell	17 800	Common Stock

INSIDER POWER
0.00
Last 3 transactions
Buy: 0 \| Sell: 175 000

Trinity Biotech PLC Korelacja

10 Najbardziej pozytywne korelacje
GRCL	0.905
NETE	0.9
JOAN	0.895
RXT	0.886
CUTR	0.885
VNDA	0.88
KPTI	0.88
UDMY	0.88
PTPI	0.878
POTX	0.878

10 Najbardziej negatywne korelacje
SVAC	-0.899
AUPH	-0.891
USCR	-0.88
RARE	-0.879
PAIC	-0.877
MLVF	-0.866
EZGO	-0.865
SUMR	-0.863
AMYT	-0.861
IIN	-0.859

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trinity Biotech PLC Finanse

Annual	2023
Przychody:	$56.83M
Zysk brutto:	$18.50M (32.56 %)
EPS:	$-15.69

FY	2023
Przychody:	$56.83M
Zysk brutto:	$18.50M (32.56 %)
EPS:	$-15.69

FY	2022
Przychody:	$74.78M
Zysk brutto:	$22.05M (29.48 %)
EPS:	$-6.08

FY	2021
Przychody:	$92.97M
Zysk brutto:	$38.08M (40.96 %)
EPS:	$0.0400

Financial Reports:

No articles found.

Trinity Biotech PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Trinity Biotech PLC Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.400	2011-06-07
Last Dividend	$0.220	2015-06-05
Next Dividend	$0	N/A
Payout Date	2015-07-01
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.190	--
Avg. Dividend % Per Year	0.00%	--
Score	0.55	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-03-31)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.55

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2011	$0.400	4.67%
2012	$0.150	1.49%
2013	$0.200	1.36%
2014	$0.220	0.88%
2015	$0.220	1.21%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.431	1.500	-8.63	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.412	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	1.650	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.60	0.800	2.02	1.613	[1 - 3]
quickRatioTTM	1.271	0.800	7.23	5.78	[0.8 - 2.5]
cashRatioTTM	0.245	1.500	9.75	10.00	[0.2 - 2]
debtRatioTTM	0.923	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	-2.41	1.000	-2.00	-2.00	[3 - 30]
operatingCashFlowPerShareTTM	-8.33	2.00	-2.78	-5.55	[0 - 30]
freeCashFlowPerShareTTM	-10.09	2.00	-5.05	-10.00	[0 - 20]
debtEquityRatioTTM	-2.29	-1.500	-9.16	10.00	[0 - 2.5]
grossProfitMarginTTM	0.334	1.000	7.76	7.76	[0.2 - 0.8]
operatingProfitMarginTTM	-0.471	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.233	1.000	-2.40	-2.40	[0.2 - 2]
assetTurnoverTTM	0.956	0.800	6.96	5.57	[0.5 - 2]
Total Score				-1.023

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.105	1.000	-0.112	0	[1 - 100]
returnOnEquityTTM	1.650	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-10.09	2.00	-3.36	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-8.33	2.00	-2.78	-5.55	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00136	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.225	1.000	-8.12	0	[0.1 - 0.5]
Total Score				-1.549

Trinity Biotech PLC

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.